1.
Guignard JP, Gouyon JB, John EG: Vasoactive factors in the immature kidney. Pediatr Nephrol 1991;5:443–446.
2.
El-Dahr SS: Development biology of the renal kallikrein-kinin system. Pediatr Nephrol 1994;8:624–631.
3.
Bhoola KD, Figueroa CD, Worthy K: Bioregulation of kinins: Kallikreins, kininogens and kininases. Pharmacol Rev 1992;44:1–80.
4.
Margolius HS: Kallikreins and kinins. Hypertension 1995;26:221–229.
5.
Figueroa CD, MacIver AG, Mackenzie JC, Bhoola KD: Localization of immunoreactive kininogen and tissue kallikrein in the human nephron. Histochemistry 1988;89:437–442.
6.
Tomita K, Pisano JJ: Binding of [3H] bradykinin in isolated nephron segments of the rabbit. Am J Physiol 1984;246:F732–F737.
7.
Edmond C, Bascands JL, Pecher C, Cabos-Boutot G, Pradelles P, Regoli D, Girolami JP: Characterization of a B2-bradykinin receptor in rat mesangial cells. Eur J Pharmacol 1990;190:381–392.
8.
Erdös EG: Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 1990;15(suppl 6):20–24.
9.
Ura N, Carretero OA, Erdös EG: Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 1987;32:507–513.
10.
Tortorolo G, Porcelli G, Curatolo P: Urinary kallikrein in premature, small at term, and normal newborns and in children; in Pisano JJ, Austen KF (eds): Chemistry and Biology of Kallikrein-Kinin System in Health and Disease. Washington, PHEW, National Institute of Health, 1974, pp 433–435.
11.
Godard C, Vallotton MB, Favre L: Urinary prostaglandins, vasopressin, and kallikrein excretion in healthy children from birth to adolescence. J Pediatr 1982;100:898–902.
12.
Vio CP, Olavarria F, Krause S, Hermann F, Grob K: Kallikrein excretion: Relationship with maturation and renal function in human neonates at different gestational ages. Biol Neonate 1987;52:121–126.
13.
Robillard JE, Lawton WJ, Weismann DN, Sessions C: Developmental aspects of the renal kallikrein-like activity in fetal and newborn lambs. Kidney Int 1982;22:594–601.
14.
El-Dahr SS, Chao J: Spatial and temporal expression of kallikrein and its mRNA during nephron maturation. Am J Physiol 1992;262:F705–F711.
15.
El-Dahr S, Yosipiv I: Developmentally regulated kallikrein enzymatic activity and gene transcription rate in maturing rat kidneys. Am J Physiol 1993;265:F146–F150.
16.
Yosipiv I, Dipp S, El-Dahr SS: Ontogeny of somatic angiotensin-converting enzyme. Hypertension 1994;23:369–374.
17.
El-Dahr SS, Figueroa CD, Gonzalez CB, Müller-Esterl W: Ontogeny of bradykinin B2 receptors in the rat kidney: Implications for segmental nephron maturation. Kidney Int 1997;51:739–749.
18.
Tóth-Heyn P, Guignard JP: Endogenous bradykinin regulates renal function in the newborn rabbit. Biol Neonate 1998;73:330–336.
19.
Kon V, Fogo A, Ichikawa I: Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993;44:545–550.
20.
Bascands JL, Pecher C, Bompart G, Rakotoarivony J, Tack JL, Girolami JP: Bradykinin-induced in vitro contraction of rat mesangial cells via a B2 receptor type. Am J Physiol 1994;267:F871–F878.
21.
Madeddu P, Anania V, Parpaglia PP, Demontis MP, Varoni MV, Pisanu G, Troffa C, Tonolo G, Glorioso N: Effects of Hoe 140, a bradykinin B2-receptor antagonist, on renal function in conscious normotensive rats. Br J Pharmacol 1992;106:380–386.
22.
Gouyon JB, Guignard JP: Theophylline prevents the hypoxemia-induced renal hemodynamic changes in rabbits. Kidney Int 1988;33:1078–1083.
23.
Huet F, Semama DS, Gouyon JB, Guignard JP: Protective effect of perindoprilat in the hypoxemia-induced renal dysfunction in the newborn rabbit. Pediatr Res 1999;45:138–142.
24.
Saugstad OD, Harvie A, Langslet A: Activation of the kallikrein-kinin system in premature infants with respiratory distress syndrome. Acta Paediatr Scand 1982;71:965–968.
25.
Tóth-Heyn P, Thonney Viani M, Guignard JP: Bradykinin and hypoxemia-induced renal changes in the newborn rabbit. Pediatr Nephrol 1998;12:377–380.
26.
Tack ED, Perlman JM: Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr 1988;112:805–810.
27.
Tóth-Heyn P, Mosig D, Guignard JP: Role of bradykinin in the neonatal renal effects of angiotensin converting enzyme inhibition. Life Sci 1998;62:309–318.
28.
Yosipiv IV, Dipp S, El-Dahr SS: Role of bradykinin B2 receptors in neonatal kidney growth. J Am Soc Nephrol 1997;8:920–928.
29.
Madeddu P, Parpaglia PP, Demontis MP, Varoni MV, Fattaccio MC, Anania V, Glorioso N: Early blockade of bradykinin B2-receptors alters the adult cardiovascular phenotype in rats. Hypertension 1995;25:453–459.
30.
El-Dahr SS, Yosipiv IV, Lewis L, Mitchell KD: Role of bradykinin B2 receptors in the developmental changes of renal hemodynamics in the neonatal rat. Am J Physiol 1995;269:F786–F792.
31.
Tóth-Heyn P, Mosig D, Guignard JP: Chronic bradykinin receptor blockade modulates neonatal renal function. Biol Neonate 2000;77:45–49.
32.
El-Dahr SS, Dipp S, Meleg-Smith S, Pinna-Parpaglia P, Madeddu P: Fetal ontogeny and role of metanephric bradykinin B2 receptors. Pediatr Nephrol 2000;14:288–296.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.